UltraShape® V3
Body Shaping via Fat Cell Destruction
“The UltraShape procedure has attracted a significant surgery-adverse patient population into my practice and consistently delivers good results with high patient satisfaction. The device paid for itself in full after six months of use; it continues to be one of the most popular and successful non-invasive procedures in my practice.”

Arie Benchetrit, MD FRCS(C)
Plastic Surgeon, Montreal, Canada

UltraShape V3
Safe and Effective Non-invasive Body Contouring

More and more patients are seeking solutions to look their best, but most do not want the downtime or complications associated with surgery. The UltraShape V3 is a non-invasive, clinically proven treatment that selectively eliminates fat cells and reduces body circumference.

The UltraShape V3 delivers pulsed focused ultrasound to mechanically (non-thermal) and selectively destroy fat cells at a designated focal point in the subcutaneous fat tissue without harming the skin, blood vessels, nerves or connective tissue. In a multi-center controlled trial and numerous other peer-reviewed published independent clinical studies, UltraShape has been clinically proven to be a safe and effective treatment for problematic areas like the abdomen, thighs and flanks.

- Clinically proven pulsed (non-thermal) focused ultrasound technology for instant, selective and long lasting fat cell destruction
- Delivers homogeneous fat reduction throughout the treatment area - no irregularities
- No bruising, swelling or downtime with pulsed focused ultrasound technology
- Comfortable and simple, “walk-in, walk-out” procedure
- Long-lasting measurable results within just a few weeks
- High patient satisfaction with no reported adverse events
Introducing! The U-Sculpt Ultrasound Transducer
A lighter weight, ergonomically designed, single focus transducer with more than 80,000 pulses for an average of 100 treatments. The U-Sculpt Transducer is designed for sculpting smaller body areas such as the upper abdomen, lower abdomen, flanks and outer thighs and utilizes focused, non-thermal ultrasound technology.

Tracking & Guidance Camera
- 3-D treatment mapping and guidance
- Achieves smooth and uniform results with no irregularities
- Provides homogeneous treatment to all of the abdomen area
- Targets a high percentage of fat cells

Tracking & Guidance Monitor
- Intuitive touchscreen
- Patient database management
- Intuitive guided user interface with integrated clinical protocol

Digital Ultrasound Pulser
- Delivers consistent high energy
- Enables future ultrasound advancement options
- Developed and based on years of clinical experience
- Multi-focus and single focus abilities

Two Optional Transducers:
- NEW! U-Sculpt UltraSound Transducer
  - Single focused ultrasound technology for mechanical fat cell destruction
  - Light weight, ergonomic design
  - Treatments of smaller anatomical areas
  - Capacity for extended pulses

- VDF™ Ultrasound Transducer
  - Delivers pulsed focused ultrasound technology for mechanical fat cell destruction
  - Targets a focal volume of fat at a defined depths
  - Customized treatment areas with handheld transducer
UltraShape V3
Pulsed, Focused Ultrasound

The UltraShape V3 works by emitting acoustic waves of ultrasonic energy that converge into a confined focal volume, targeting only subcutaneous fat at a controlled depth. Unlike traditional ultrasound technology, UltraShape V3’s energy transmits pulsed ultrasound, allowing control over temperature elevation (less than 0.5°C increase) and enabling fat destruction to occur instantly, selectively and mechanically (non-thermal).

VDF™ Single-Focus Ultrasound
- Designed to treat fat at a focal point of 15mm under the skin

VDF Multi-Focus Ultrasound
- Designed to treat multiple depths and more fat volume in a single pulse

U-Sculpt Single Focus Ultrasound
- Lighter weight, ergonomically designed
- Intended for sculpting small body areas such as upper and lower abdomen, flanks and outer thighs

Natural Fat Clearance²
The UltraShape procedure is based on a natural fat clearance process where triglycerides and cell debris from the immediately destroyed fat cells are processed by the body’s natural physiological and metabolic pathways. These pathways are the same that handle fat during weight loss. Results from UltraShape’s peer-reviewed published multi-center controlled clinical trial and other independent clinical studies show that the released triglycerides do not accumulate to a clinically significant extent in the blood or liver.³
Immediate, Selective Fat Cell Destruction

The clinical efficacy and safety profile of UltraShape is supported by peer-reviewed, published, multi-center controlled clinical trials and independent clinical studies of over 600 patients.

A. Histology confirms UltraShape technology instantly and selectively destroys fat cells alone.¹

B. Gross pathology confirms treatment with pulsed (non-thermal) focused ultrasound causes immediate fat tissue destruction.

C. CT scans demonstrate fat reduction

“My clinical study demonstrated measurable circumference reduction in all patients. These results were further supported by CT scans in a subset of patients showing a sustained reduction in fat thickness. In addition, 94% of patients reported satisfaction with the UltraShape procedure confirming that it is meeting patient expectations and the high demand for safe and effective non-invasive fat reduction in today’s aesthetic practice.”

Hector Leal-Silva, M.D., Dermatologic Surgeon, Monterrey, Mexico
Clinically Proven Safe and Effective
UltraShape Clinical Studies - Abdomen, Flanks and Thighs

Effectiveness
- Histological evidence confirms immediate fat cell destruction without damage to surrounding blood vessels, nerves and connective tissue
- CT scans demonstrate fat thickness reduction
- Average circumference reduction ranges from 3.5 to 6.3 cm\(^1\) (in abdomen, flanks and thighs)

Satisfaction
- Average patient satisfaction range from 86%-94\%\(^1\) (in abdomen flanks and thighs)

Safety
- Majority of patients reported no pain or discomfort during or following treatment (in all above studies)
- Normal blood profiles confirmed safe fat clearance\(^3\)
- Excellent safety profile - no reported serious adverse events.
- Over 300,000 treatments performed worldwide

<table>
<thead>
<tr>
<th>Investigator</th>
<th>Year</th>
<th>Patient Population</th>
<th>Average Circumference Reduction</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leal H.(^a)</td>
<td>2009</td>
<td>24</td>
<td>3.0-3.4 cm (1 combination therapy treatment)</td>
<td>96% &gt; 1.5 cm circumference reduction 100% patient satisfaction</td>
</tr>
<tr>
<td>Moreno-Moraga J.(^b)</td>
<td>2006</td>
<td>30</td>
<td>3.95 cm</td>
<td>100% measurable and visual improvement</td>
</tr>
<tr>
<td>Ascher B.(^b)</td>
<td>2007-08</td>
<td>25</td>
<td>3.58 cm</td>
<td>83% &gt; 1.0 cm circumference reduction</td>
</tr>
<tr>
<td>Leal-Silva H.(^a)</td>
<td>2007-08</td>
<td>36</td>
<td>5.0 cm</td>
<td>100% measurable reduction 94% patient satisfaction</td>
</tr>
<tr>
<td>Ad El D.(^a)</td>
<td>2008</td>
<td>26</td>
<td>3.96 cm</td>
<td>90% &gt; 2.0 cm circumference reduction</td>
</tr>
<tr>
<td>Mulholland S.(^b)</td>
<td>2008</td>
<td>21</td>
<td>3.48 cm</td>
<td>86% patient satisfaction</td>
</tr>
<tr>
<td>Inglefield C.(^b)</td>
<td>2005-06</td>
<td>148</td>
<td>6.3 cm</td>
<td>93% patient satisfaction</td>
</tr>
<tr>
<td>De Almeida G.(^b)</td>
<td>2007-08</td>
<td>20</td>
<td>5.4 cm</td>
<td>100% measurable reduction 86% patient satisfaction</td>
</tr>
<tr>
<td>Benchetrit A.(^b)</td>
<td>2007-09</td>
<td>109</td>
<td>4.5 cm</td>
<td>96% measurable reduction 86% patient satisfaction</td>
</tr>
</tbody>
</table>

\(^a\) Company controlled sponsored clinical studies
\(^b\) Other publications, peer reviewed and/or presented at scientific conferences
\(^c\) All of the studies were performed with single focused ultrasound
“As a long time and satisfied UltraShape user, I find the new U-Sculpt transducer a great enhancement. U-Sculpt is light and easy to move around and enables me to treat small areas which were not reachable with the larger transducer. In addition, the new treatment set up using the gel and straps, minimizes the preparation time significantly, a fact that is well appreciated by both my patients and my staff.”

Chris Inglefield, MD., Plastic Surgeon

Clinical Results


Syneron and Candela are the global leaders in the aesthetic medical device marketplace.

We are one company with two distinctive brands. We combine a level of innovation, expertise and customer understanding superior to that of any company in our industry.

Financial stability, through our aligned resources, allows our new company to offer customers the broadest available product portfolio, the best global service organization and an expansive worldwide distribution network.

Together, we are more market responsive than ever before. We know how to quickly innovate safe and effective products to meet a variety of needs and price points. We are even stronger at anticipating future market trends to help support our customers and their patients. With new breakthrough technologies currently in the pipeline, we are ideally positioned to maintain our global leadership and continue to help you grow your practice.

Syneron and Candela have offices and distributors around the world.

**UltraShape V3 System Specifications**

<table>
<thead>
<tr>
<th>Key Standards</th>
<th>• IEC 60601-1 • IEC 60601-1-2</th>
</tr>
</thead>
</table>
| Certifications | • CE (0344) mark  
                  • CSA  
                  • CB Scheme |
| Focused ultrasound technology | • Ultrasound operation frequency: 200 ± 30 KHz  
                               • Input voltage: Set by technician during installation:  
                               110-120 V or 200-240 V, 50/60 Hz |
| Dimensions | • System Console: Less than 130 kg  
              • VDF Transducer: Less than 2.5 kg  
              • Usculpt Transducer: Less than 1 kg |

infois@syneron.com | www.syneron-candela.com